Bio-Technology General Corp. Announces Oxandrolone Presentation At The MASCC-ISOO 14th International Symposium: Supportive Care in Cancer.

Business Editors & Health/Medical Writers

BIOWIRE2K

Bio-Technology General Corp. (NASDAQ:BTGC) announces a presentation on its product oxandrolone (Oxandrin(R)) in involuntary weight loss in cancer patients at the 14th International Symposium: Supportive Care In Cancer at the combined meeting of The Multinational Association of Supportive Care in Cancer (MASCC) and The International Society of Oral Oncology (ISOO).

The Symposium is taking place June 23-26, 2002, in Boston, MA.

Data from an ongoing, open label clinical study on the effect of oxandrolone on weight, lean tissue, performance status and quality of life scores in cancer-related weight loss will be presented on Wednesday, June 26, 2002, as part of a session on cachexia from 9:30 am - 11:30 am. The session will be chaired by Charles Loprinzi, M.D., and Aminah Jatoi, M.D., both of the Mayo Clinic.

Oxandrolone is a synthetic derivative of testosterone indicated as adjunctive therapy to promote weight gain after weight loss following extensive surgery, chronic infections, or severe trauma, and in some patients who without definite pathophysiologic reasons fail to gain or to maintain normal weight, to offset the protein catabolism associated with prolonged administration of corticosteroids, and for the relief of the bone pain frequently accompanying osteoporosis.

Bio-Technology General Corp., a leading biopharmaceutical company, develops, manufactures and markets genetically engineered and other products for human health care. BTG's products are marketed worldwide. Products sold in the United States are Oxandrin(R) (oxandrolone, USP), marketed by BTG and by the Ross Products Division of Abbott Laboratories under a co-marketing agreement, Delatestryl(R) (testosterone enanthate), marketed by BTG, Mircette(R) (oral contraceptive), marketed by Organon, Inc., and BioLon(TM) (sodium hyaluronate), marketed by Akorn, Inc. Products sold internationally are Bio-Tropin(TM) (recombinant human growth hormone), BioLon(TM) (sodium hyaluronate), Bio-Hep-B(TM) (hepatitis B vaccine), Arthrease(TM) (sodium hyaluronate for osteoarthritis), and Silkis(R) (vitamin D derivative). BTG's news releases and other information are available on the Company's website at www.btgc.com.

Arthrease is a trademark of DePuy Orthopaedics, Mircette is a registered trademark of Organon, Inc., Silkis is a registered trademark of Galderma.

You should not rely on forward-looking statements contained in this press release including, but not limited to, statements regarding the safety and clinical activity of oxandrolone in adjunctive therapy of cancer-associated weight loss. Oxandrolone may prove safe and effective in only certain tumor types, if any.

Statements in this news release concerning the Company's business outlook or future economic performance, anticipated profitability, revenues, expenses or other financial items; and statements concerning assumptions made or expectations as to any future events, conditions, performance or other matters, are "forward-looking statements" as that term is defined under the Federal Securities Laws. Forward-looking statements are subject to risks, uncertainties and other factors that could cause actual results to differ materially from those stated in such statements. Such risks, uncertainties and factors include, but are not limited to, changes and delays in product development plans and schedules, customer acceptance of new products, changes in pricing or other actions by competitors, patents owned by the Company and its competitors, and general economic conditions, as well as other risks detailed in the Company's filings with the Securities and Exchange Commission.